
Please try another search
PegBio Co., Ltd., a biopharmaceutical company, focuses on the research and development of medicines for chronic diseases in China. The company’s products include PB-119, a glucagon like peptide 1 receptor agonist for the treatment of type 2 diabetes mellitus and obesity. The company’s PB-718 that is in b/IIa clinical trials for the treatment non-alcoholic steatohepatitis (NASH) (PB-718 for obesity and NASH); and PB-1902 that is in phase II clinical trials for the treatment of opioids constipation and obesity. It is also developing GLP-1 for the first-line treatment of type 2 diabetes mellitus and obesity; and PB-722 that has completed the FDA orphan drug qualification certification for use in the treatment of congenital hyperinsulinemia. Additionally, it is also conducting preclinical studies test on PB-2301, a GLP-1/glucose-dependent insulinotropic polypeptide and PB-2309, a GLP-1/GIP/ glucagon triple receptor agonist for the treatment of type 2 diabetes mellitus, NASH, and obesity. The company was incorporated in 2008 and is based in Hangzhou, China.
Name | Age | Since | Title |
---|---|---|---|
Min Xu | 60 | 2008 | Executive Chairman of the Board & GM |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review